How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,813 results for

Adrenal Mass

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3561. Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

nonmeasurable: Bone lesions Leptomeningeal disease Ascites Pleural or pericardial effusions Abdominal masses unconfirmed by imaging techniques Cystic lesions Previously irradiated brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant (...) concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy except steroids for adrenal failure, hormones for non-cancer-related conditions (e.g., insulin for diabetes) or intermittent dexamethasone as an antiemetic Radiotherapy: Prior radiotherapy for brain metastasis allowed if neurologically stable and off steroids No concurrent palliative radiotherapy Surgery: Not specified Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2001 Clinical Trials

3562. Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed Hodgkin's lymphoma that is recurrent or refractory after standard chemotherapy Core biopsy is acceptable if adequate tissue is obtained for primary diagnosis and immunophenotyping Bone marrow biopsy is not acceptable as sole means of diagnosis Measurable disease Tumor mass greater than 1 cm (...) contraception PRIOR CONCURRENT THERAPY: No prior gemcitabine, vinorelbine, or doxorubicin HCl liposome No other concurrent chemotherapy Endocrine therapy: No concurrent hormones except for nondisease-related conditions (e.g., insulin for diabetes) or steroids for adrenal failure No concurrent dexamethasone or other steroidal antiemetics Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2000 Clinical Trials

3563. Steroid Treatment for Kidney Disease

and children greater than 13.0 years and first void urine samples in children less than 13.0 years. Patients will be evaluated for manifestations of steroid toxicity, including growth rate (children), ophthalmologic complications, adrenal suppression, osteoporosis, a vascular necrosis, and psychological disturbances. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 8 participants Allocation: Randomized Intervention Model: Parallel (...) , and reduced nephron mass; the rationale is that these FSGS variants are considered refractory to steroids. Proteinuria: patients must have nephrotic range proteinuria. Baseline tests will be obtained when patients have been off all immunosuppressive therapy for greater than or equal to 1 month. Renal function: estimated GFR must be greater than or equal to 40 ml/min/1.73m(2) at the time of study entry; In children weighing less than 40kg, GFR will be estimated by the Schwartz formula and expressed as GFR

2003 Clinical Trials

3564. MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

Radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma 18 years of age or older Progressive prostate cancer as defined by the presence of one or more of the following despite castrate levels of testosterone (testosterone <50 ng/dL): Progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical examination or X-ray and CT scan or MRI) Progressive bone metastasis (presence of new lesion(s) on a bone scan) Progressive PSA levels (as defined in Section (...) 3.6.1) Subjects who have received an anti-androgen must have shown progression of disease following discontinuation of the anti-androgen Subjects must remain on luteinizing hormone-releasing hormone (LHRH) analog therapy for the duration of the trial unless surgically castrate Agree to use an effective barrier method of contraception. Exclusion criteria: Testosterone >50 ng/dL Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing Use of PC-SPES within 4 weeks of dosing

2003 Clinical Trials

3565. Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

that are accessible to needle, punch or other limited biopsy, be at low risk for biopsy and be willing to undergo tumor core needle biopsy, punch or other similar biopsy pre-vaccination and again post-vaccination. Such sites may include skin and soft tissue metastases, adrenal gland metastases, peripheral lymph nodes (supraclavicular, axillary, or inquinal), a pulmonary lesion at low risk for complications defined as lesions greater than 1.5 cm surrounded by aerated lung, pleural based masses greater than 1.5 cm

2003 Clinical Trials

3566. Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

The following are not considered measurable disease: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions Tumor lesions in a previously irradiated field PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 2 (...) No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy except steroids for adrenal failure or septic shock, hormones for non-disease-related conditions (e.g., insulin for diabetes), or glucocorticosteroids as antiemetics Radiotherapy: See Disease Characteristics No prior radiotherapy for NSCLC Surgery: At least 2 weeks since prior exploratory thoracotomy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2002 Clinical Trials

3567. CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

by CT scan or MRI OR at least 1.5 cm by physical exam One of the following measurement parameters may be used: Splenic enlargement may be used as a measurement parameter if spleen is palpable at least 3.0 cm across left costal margin Malignant lymphocytosis may be used as a measurement parameter if absolute lymphocyte count is at least 5,000/mm^3 No known CNS involvement (parenchymal mass or leptomeningeal involvement) Performance status - ECOG 0-2 At least 3 months See Disease Characteristics (...) Disease Characteristics See Biologic therapy At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin) No other concurrent chemotherapy for MCL Concurrent corticosteroids for adrenal insufficiency allowed See Disease Characteristics At least 3 weeks since prior radiotherapy No concurrent radiotherapy for MCL Any number of prior treatments allowed No other concurrent investigational or commercial agents for MCL No concurrent drugs that induce cytochrome p450

2002 Clinical Trials

3568. Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

/pericardial effusion Abdominal masses not confirmed and followed by imaging Cystic lesions Performance status - CTC 0-2 WBC at least 2,000/mm^3 Platelet count at least 75,000/mm^3 Bilirubin no greater than upper limit of normal (ULN) AST no greater than 2.5 times ULN Creatinine no greater than 2.0 mg/dL Not pregnant or nursing Fertile patients must use effective contraception No baseline neuropathy or cerebellar dysfunction greater than grade 1 At least 4 weeks since prior immunotherapy No prior (...) carboxyamidotriazole No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) Concurrent epoetin alfa allowed At least 4 weeks since prior chemotherapy No concurrent chemotherapy No concurrent hormonal therapy except steroids for adrenal failure or hormones for conditions not related to disease (e.g., insulin for diabetes) At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy See Disease Characteristics At least 4 weeks since prior surgery Contacts and Locations Go to Information from

2000 Clinical Trials

3569. Evaluation of Chronic Orthostatic Intolerance

studies using sensors applied to the skin and a pressure cuff around a limb, blood volume studies using injection of radioactively labeled human serum albumin and gene studies to look for genetic abnormalities associated with certain proteins. Imaging studies, including CT scan of the adrenal glands, heart ultrasound, and PET scanning. Electrocardiogram Microdialysis to measures levels of chemicals in the body fluid of certain tissues. A thin tube is inserted into the skin and a solution is passed (...) Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria INCLUSION CRITERIA: The subjects are patients with COI and adult healthy volunteers of similar age, gender, and body mass. Participation in this protocol is offered to people 18 years old or older, independently of gender, race, age, ethnicity, religion, or any other demographic or sociopolitical classifications. The subjects in the second off-site study are family members

2003 Clinical Trials

3570. Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

lung cancer At least 1 unidimensionally measurable lesion At least 20 mm by conventional techniques OR At least 10 mm by spiral CT scan Lesions considered nonmeasurable include: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions Tumor lesions situated in a previously irradiated area Must not be considered for combined chemotherapy and radiotherapy No active CNS metastases PATIENT (...) patients must use effective contraception No concurrent uncontrolled illness No known sensitivity to sulindac PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No prior chemotherapy for small cell lung cancer No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal agents except: Steroids for adrenal failure Hormones for nondisease-related conditions (e.g., insulin for diabetes) Intermittent use of dexamethasone as an antiemetic

2002 Clinical Trials

3571. Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

renal cell carcinomas allowed No pure sarcomas No collecting duct (duct of Bellini) tumors, oncocytomas, or transitional cell tumors Measurable disease At least 20 mm by conventional techniques OR At least 10 mm by spiral CT scan Nonmeasurable lesions include the following: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions Patients with known brain metastases (...) No concurrent hormones (e.g., megestrol) except steroids for adrenal failure, hormones for nondisease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic Radiotherapy See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered Prior radiotherapy to any lesion that may produce disability (e.g., unstable femur) allowed No concurrent palliative radiotherapy Surgery See Disease Characteristics At least 4 weeks since prior major surgery

2002 Clinical Trials

3572. Effects of Dietary Carbohydrate and Fat on Hormones

Clinical Center (CC) Study Details Study Description Go to Brief Summary: This study will try to determine if intake of dietary fats or carbohydrates influences the tendency to gain weight or accumulate body fat. It will examine how the hormones that regulate weight may change with a shift from a balanced diet to one that is low in fat or carbohydrate, irrespective of caloric intake. Men and women between the ages of 18 and 40 years with a body mass index of 30 to 49 kg/m2 may be eligible (...) , pituitary, ovarian/testicular and adrenal problem Acute infections Irregular menstrual cycles (greater than 7 day menses, intervals greater than 35 or less than 21 days) A weight change of greater than 2% within the past 2 months. Use of prescription medications or other drugs/supplements including acetaminophen or alcohol that would, in the judgement of study investigators, interfere with study objectives Major (greater than 3 hours/week) athletic/physical exercise activities. Eating patterns

2001 Clinical Trials

3573. S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

or lymphoma for which standard curative or palliative measures do not exist or are no longer effective Pathological confirmation of diagnosis not required in patients with liver mass, raised alpha-fetoprotein levels (at least 500 ng/mL), and positive serology for hepatitis consistent with a diagnosis of hepatocellular carcinoma Any solid tumor or lymphoma tumor type eligible Must have had thoracic and upper abdominal CT scan, including entire liver and adrenals, within 28 days before study entry Patients

2002 Clinical Trials

3574. Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

). [ Time Frame: Up to 5 years ] Complete Response (CR) is defined using response criteria (the neurologic examination and the Magnetic resonance imaging (MRI) and/or Computerized Tomography (CT)), total disappearance of all tumor with patient off corticosteroids or only on adrenal replacement maintenance. Partial Response (PR) is defined using response criteria (the neurologic examination and the MRI and/or CT), >=50% reduction in product of perpendicular diameters of contrast enhancement or mass (...) % confidence interval estimated using the Duffy-Santer algorithm. Progression is defined using response criteria (the neurologic examination and the MRI and/or CT), >25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions. Secondary Outcome Measures : Confirmed Response (i.e., an Objective Status of Complete Response (CR), Partial Response (PR), or Regression (REGR) on 2 Successive Evaluations at Least 4 Weeks Apart After the Start of Study Treatment

2002 Clinical Trials

3575. Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

or vertebral body documented by CT scan, MRI or transesophageal ultrasound T4 involvement of the mediastinum may also be accepted by CT or MRI criteria if, in absence of the above organ involvement, there is soft tissue extension directly into the mediastinal space; radiographic criteria for involvement of main pulmonary artery or vein is allowed only if there is a mediastinal soft tissue mass Patients must not have malignant pleural effusions; NOTE: the only exception is pleural effusion only on CT scan (...) must be > 800 cc based on the quantitative split function testing within 42 days prior to registration WBC >= 3,000/ul ANC >= 1,200/ul Platelet count >= 100,000/ul All patients must have a CT of upper abdomen to exclude metastatic disease involving the contralateral chest, liver or adrenals (if chest CT is performed including complete liver and adrenals in the report, a separate CT of upper abdomen is not necessary) within 42 days prior to registration All patients must have a Zubrod Performance

2001 Clinical Trials

3576. Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

disease greater than 1 cm Nonmeasurable disease includes the following: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal masses not confirmed and followed by imaging techniques Cystic lesions Lesions in a previously irradiated area PATIENT CHARACTERISTICS: Age: 18 to 69 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Hepatitis B surface antigen and hepatitis (...) PRIOR CONCURRENT THERAPY: Biologic therapy: No more than 1 prior dose of rituximab Chemotherapy: No more than 1 prior cycle of chemotherapy At least 3 weeks since prior chemotherapy No other concurrent chemotherapeutic agents Endocrine therapy: No chronic use of oral corticosteroids for ongoing medical condition No concurrent hormonal therapy except for non-lymphoma-related conditions (e.g., insulin for diabetes) Other concurrent corticosteroids for adrenal failure, diffuse alveolar hemorrhage

2001 Clinical Trials

3577. Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

-ray) OR 10 mm by spiral CT scan or MRI The following are considered nonmeasurable disease: Small lesions Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions Irradiated lesions, unless progression is documented after radiotherapy RCC paraffin tissue blocks or unstained slides must be available No evidence of prior or concurrent CNS metastases by MRI or CT scan (...) corticosteroid therapy except the following: Topical and inhaled steroids Replacement therapy for adrenal insufficiency No concurrent hormones except those administered for nondisease-related conditions (e.g., insulin for diabetes) Radiotherapy See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered Prior palliative radiotherapy to metastatic lesions allowed provided at least 1 measurable or nonmeasurable lesion remains untreated No concurrent palliative radiotherapy Surgery

2003 Clinical Trials

3578. A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer

Adult Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria Each subject must meet the following inclusion criteria to be eligible for enrollment in the study: Histologic diagnosis (recent or remote) of prostate adenocarcinoma Progressive prostate cancer on physical exam, imaging studies and/or rising PSA, as defined by the presence of one or more of the following: Progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical (...) , or abstinence. Exclusion Criteria Subjects meeting any of the following exclusion criteria are not to be enrolled in the study: Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of enrollment Use of PC-SPES (herbal supplement) within 4 weeks of enrollment Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of enrollment Use of anti-androgen therapy (e.g., flutamide, bicalutamide, nilutamide) within 6 weeks of enrollment Prior monoclonal antibody administration

2003 Clinical Trials

3579. Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

within 1 month prior to baseline Treatment with immunomodulator drugs (interleukins, corticosteriods for indications other than the treatment of adrenal insufficiency) in the 4 weeks prior to baseline. G-CSF and epoetin use are permitted. Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG, clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that ended more than 12 weeks prior to screen. Hepatic mass suggestive of hepatocellular

2001 Clinical Trials

3580. Gefitinib in Treating Patients With Malignant Mesothelioma

/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal masses not confirmed and followed by imaging techniques Cystic lesions No known brain metastases Performance status - CTC 0-1 Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 2.5 times ULN Creatinine no greater than 1.5 times ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac (...) agents (including bleomycin) allowed No prior systemic cytotoxic chemotherapy for malignant mesothelioma No concurrent chemotherapy At least 1 week since prior CYP3A4 inducers (e.g., dexamethasone, glucocorticoids, progesterone) No concurrent CYP3A4 inducers (e.g., dexamethasone) No concurrent hormonal therapy (e.g., tamoxifen) except steroids for adrenal failure or hormones for non disease-related conditions (e.g., insulin for diabetes) See Disease Characteristics At least 4 weeks since prior

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>